NO20033950L - Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft - Google Patents

Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft

Info

Publication number
NO20033950L
NO20033950L NO20033950A NO20033950A NO20033950L NO 20033950 L NO20033950 L NO 20033950L NO 20033950 A NO20033950 A NO 20033950A NO 20033950 A NO20033950 A NO 20033950A NO 20033950 L NO20033950 L NO 20033950L
Authority
NO
Norway
Prior art keywords
cancer
polyphenols
treatment
nutritional composition
treating cancer
Prior art date
Application number
NO20033950A
Other languages
English (en)
Other versions
NO20033950D0 (no
Inventor
Matthias Rath
Alexandra Niedzwiecki
Shrirang Netke
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23366808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20033950(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of NO20033950D0 publication Critical patent/NO20033950D0/no
Publication of NO20033950L publication Critical patent/NO20033950L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20033950A 2002-01-11 2003-09-05 Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft NO20033950L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34814302P 2002-01-11 2002-01-11
PCT/EP2003/000236 WO2003057201A2 (en) 2002-01-11 2003-01-13 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer

Publications (2)

Publication Number Publication Date
NO20033950D0 NO20033950D0 (no) 2003-09-05
NO20033950L true NO20033950L (no) 2003-11-10

Family

ID=23366808

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033950A NO20033950L (no) 2002-01-11 2003-09-05 Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft

Country Status (27)

Country Link
US (2) US7041699B2 (no)
EP (1) EP1465614B1 (no)
JP (1) JP2005519055A (no)
KR (1) KR20040073559A (no)
CN (1) CN100377706C (no)
AT (1) ATE382343T1 (no)
AU (1) AU2003235762B2 (no)
BR (1) BR0302672A (no)
CA (1) CA2471932A1 (no)
DE (1) DE60318387T2 (no)
EE (1) EE200400032A (no)
ES (1) ES2298519T3 (no)
HK (1) HK1086489A1 (no)
HR (1) HRP20040704A2 (no)
HU (1) HUP0500498A3 (no)
IL (1) IL162646A0 (no)
LT (1) LT5240B (no)
LV (1) LV13248B (no)
MX (1) MXPA04006717A (no)
NO (1) NO20033950L (no)
NZ (1) NZ533737A (no)
PL (1) PL215159B1 (no)
RU (1) RU2301666C2 (no)
UA (1) UA80692C2 (no)
WO (1) WO2003057201A2 (no)
YU (1) YU75003A (no)
ZA (1) ZA200405075B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034310B2 (en) * 2002-02-21 2015-05-19 Stephen B. Cantrell Interferon-statin combination cancer therapy
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
MXPA06002534A (es) * 2003-09-05 2006-06-20 Matthias Rath Composicion farmaceutica que comprende i.a. vitamina c, magnesio, extracto de te verde para retardar enfermedades cardiovasculares.
US20050176674A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
US8377904B2 (en) 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
KR100601080B1 (ko) * 2004-08-26 2006-07-19 가톨릭대학교 산학협력단 (-)-에피갈로카테킨 갈레이트를 유효성분으로 하는류마티스성 관절염 치료제
JP5156392B2 (ja) 2005-02-03 2013-03-06 トポターゲット ユーケー リミテッド Hdac阻害剤を用いる併用療法
BRPI0520221A2 (pt) 2005-04-11 2009-04-22 Matthias Rath uso de uma composiÇço nutriente que compreende polifenàis de chÁ verde para tratamento de osteossarcoma
WO2006108429A1 (en) * 2005-04-11 2006-10-19 Matthias Rath Nutrient composition for treating sarcoma and prostate cancer
EA018982B1 (ru) 2005-05-13 2013-12-30 Топотаргет Юкей Лимитед Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов
EP1924257A4 (en) * 2005-07-26 2012-08-08 Mitsui Norin Kk STABILIZED 3-HYDROXYFLAVAN COMPOSITIONS AND METHOD THEREFOR
WO2007033356A2 (en) * 2005-09-14 2007-03-22 Mitsui Norin Co., Ltd Compositions and methods for green tea catechins for modification of detoxification enzymes
WO2007054719A2 (en) * 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
US20070212426A1 (en) * 2006-03-10 2007-09-13 Matthias Rath Composition and method of retarding viral activity and reducing viral replication
WO2007147128A2 (en) 2006-06-16 2007-12-21 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
GB0615781D0 (en) * 2006-08-09 2006-09-20 Coressence Ltd Prebiotic composition
US20080114054A1 (en) * 2006-11-14 2008-05-15 Rath Microbes Compositions and methods for reducing antimicrobial resistance of microbes
US8617544B2 (en) * 2007-05-01 2013-12-31 Richard L. Kozlenko Compositions and methods for controlling lipid metabolism
GB0710536D0 (en) 2007-06-01 2007-07-11 Veritron Ltd Plant extract and its therapeutic use
CA2700173C (en) * 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
CN102083428A (zh) * 2008-03-07 2011-06-01 顶标公司 采用长时间连续输液Belinostat进行治疗的方法
RU2395281C2 (ru) * 2008-09-04 2010-07-27 Всеволод Иванович Киселев Фармацевтическая композиция для лечения диспластических процессов шейки матки
ES2534245T3 (es) 2008-11-04 2015-04-20 Vymedic, Llc Formulaciones de suplemento antiviral
US8677463B2 (en) * 2008-12-05 2014-03-18 At&T Intellectual Property I, Lp System and method for managing multiple sub accounts within a subcriber main account in a data distribution system
JP2009143928A (ja) * 2008-12-26 2009-07-02 Kyushu Univ ガロイルカテキン類の抗酸化活性の促進方法
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CN101874822A (zh) * 2009-04-27 2010-11-03 玫琳凯有限公司 植物性抗痤疮制剂
IT1397522B1 (it) * 2009-12-21 2013-01-16 Solartium Entpr Ltd Uso di una combinazione per il trattamento dell'osteoartrosi
GB201015784D0 (en) 2010-09-20 2010-10-27 Bionature E A Ltd Anti-cancer compounds
EP2793848B1 (en) 2011-12-19 2019-06-26 Mary Kay, Inc. Navy bean extract to whiten the skin and improve skin tone
RU2522547C1 (ru) * 2012-11-12 2014-07-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Фармакологическая геропротекторная композиция и способ ее получения
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
JP2016519092A (ja) * 2013-03-18 2016-06-30 デンタルメッド ファーム ホールディング リミテッド 組成物におけるn−アセチルシステイン誘導体とクランベリーポリフェノールとの組み合わせ、並びに歯周疾患及びインプラント周囲炎を予防及び処置するための方法
BE1023772B9 (fr) * 2013-05-17 2017-08-02 Valore Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
IN2013MU01528A (no) * 2013-07-26 2015-06-26 Tata Memorial Ct
GB2520794A (en) * 2013-07-26 2015-06-03 Tata Memorial Ct Plant poly-phenol and copper (II) mediated degradation of DNA and RNA
KR102323049B1 (ko) 2014-03-10 2021-11-05 마리 케이 인코포레이티드 피부 라이트닝 조성물
BE1022579A9 (fr) * 2014-11-10 2016-10-06 Valore Composition antimétastatique comprenant au moins un composé de type flavanol
CN105061533B (zh) * 2015-09-18 2018-02-09 福州大学 六甲氧基二氢黄酮‑鼠李糖基‑鼠李糖苷及其应用
CN106138036A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酸酯在制备抗肿瘤药物中的应用
CA3228010A1 (en) * 2016-10-03 2018-04-12 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
CN111479577A (zh) 2017-06-13 2020-07-31 夏滉 用于增强癌症放疗的组合物和方法
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
KR20200079229A (ko) 2017-06-13 2020-07-02 호운 사이먼 샤 암 화학요법을 강화시키기 위한 조성물 및 방법
CN111529709A (zh) * 2020-06-03 2020-08-14 北京易思腾翻译服务有限公司 一种可用于体重控制且可逆转动脉粥样硬化的组合物
WO2022124386A1 (en) * 2020-12-07 2022-06-16 L' Oreal Composition comprising ascorbic acid and cyclic amino acid
IT202200010592A1 (it) * 2022-05-23 2023-11-23 Neilos S R L “Composizione nutraceutica o farmaceutica per l’infertilità maschile”

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4243363A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Behandlungsverfahren für Hauttrockenheit
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
EP0938897A1 (en) * 1997-12-26 1999-09-01 Japanese Foundation For Cancer Research Telomerase inhibitor
AT407821B (de) * 1998-03-24 2001-06-25 Franz Dr Stueckler Mittel auf der basis von naturstoffen
AU4043900A (en) * 1999-03-30 2000-10-16 Purdue Research Foundation Compositions containing tea catechins as cancer specific proliferation inhibitors
KR20020016833A (ko) 1999-06-15 2002-03-06 뉴트리-로직스, 인크. 발병 감소에 유용한 영양 제제, 관련 치료 방법 및 성분스크리닝 방법
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
EP1195159B1 (en) * 2000-10-09 2006-05-31 Rath, Matthias, Dr. med. Therapeutic combination of ascorbate with lysine and arginine for prevention and treatment of cancer
WO2007076492A2 (en) 2005-12-28 2007-07-05 Sandisk Corporation Methods and systems for writing non-volatile memories for increased endurance

Also Published As

Publication number Publication date
NZ533737A (en) 2006-02-24
DE60318387D1 (de) 2008-02-14
US7041699B2 (en) 2006-05-09
LT5240B (lt) 2005-07-25
PL215159B1 (pl) 2013-10-31
MXPA04006717A (es) 2004-11-10
HUP0500498A2 (hu) 2005-08-29
AU2003235762B2 (en) 2008-10-02
HRP20040704A2 (en) 2004-10-31
LV13248B (en) 2005-06-20
US20030170319A1 (en) 2003-09-11
KR20040073559A (ko) 2004-08-19
EP1465614B1 (en) 2008-01-02
EE200400032A (et) 2004-04-15
WO2003057201A3 (en) 2004-03-11
UA80692C2 (en) 2007-10-25
NO20033950D0 (no) 2003-09-05
CN100377706C (zh) 2008-04-02
RU2301666C2 (ru) 2007-06-27
ATE382343T1 (de) 2008-01-15
WO2003057201A2 (en) 2003-07-17
EP1465614A2 (en) 2004-10-13
YU75003A (sh) 2006-08-17
HK1086489A1 (en) 2006-09-22
BR0302672A (pt) 2004-02-25
HUP0500498A3 (en) 2013-01-28
JP2005519055A (ja) 2005-06-30
ES2298519T3 (es) 2008-05-16
PL371282A1 (en) 2005-06-13
AU2003235762A1 (en) 2003-07-24
ZA200405075B (en) 2006-07-26
IL162646A0 (en) 2005-11-20
LT2004076A (en) 2005-02-25
DE60318387T2 (de) 2008-12-18
US20060142212A1 (en) 2006-06-29
CN1731989A (zh) 2006-02-08
CA2471932A1 (en) 2003-07-17
RU2004124384A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
NO20033950L (no) Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft
Park et al. Extract of Punica granatum inhibits skin photoaging induced by UVB irradiation
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
BRPI0409969A (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
IL183953A0 (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical, or stored blood
BR0315580A (pt) Derivados de metileno uréia
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
NO20030301L (no) Nye heteroarylderivater og anvendelse derav som farmasöytika
BR0007589A (pt) Inibidores da proliferação de células
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
HK1063185A1 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
DE60140234D1 (de) Epigallocatechin-gallate zur hemmung von angiogenese
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
WO2006021888A3 (en) Dihydrofolate reductase inhibition by epigallocatechin gallate compounds
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
BRPI0520221A2 (pt) uso de uma composiÇço nutriente que compreende polifenàis de chÁ verde para tratamento de osteossarcoma
DE602004004440D1 (de) Pyrane als Flüssigkristalle
MX2021010491A (es) Tratamiento de fibromas con vitamina d y un agente tal como galato de epigalocatequina (egcg).
DE60331654D1 (de) Nicht-radioaktives Strontiummittel zur Behandlung von Krebs
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application